Navigation Links
SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
Date:4/11/2012

Boulder, CO April 11, 2012 -- In a scientific paper published today in the journal PLoS ONE, researchers from SomaLogic and the University of Washington in Seattle describe the first application of the SOMAscanTM proteomic assay technology to tissue samples. Working with both tumor and non-cancerous lung samples from patients with non-small cell lung cancer (NSCLC), they identified significant expression changes in 36 proteins, including 13 proteins not previously associated with the disease. These findings reveal significant new information about the biology underlying NSCLC, and have implications for improving early diagnosis and treatment.

"Early detection of NSCLC can dramatically improve the prognosis for patients with the disease, as has been shown recently through the use of CT-scans in a high-risk population of heavy smokers," said Sheri Wilcox, Ph.D., Director of Discovery Sciences at SomaLogic. "However, this approach has a high false-positive rate, which can result in overdiagnosis and unnecessary treatment. We set out to find additional molecular 'biomarkers' that would help guide both the use of imaging techniques as well as choosing appropriate treatments."

In their study, the researchers found 36 protein biomarkers that showed significant expression differences between the tumor tissue and non-cancerous lung tissue samples taken from the same patients. These potential biomarkers were discovered by simultaneously measuring the expression levels of 820 different proteins in all samples examined, using SomaLogic's SOMAscan proteomic assay. Of these 36 potential biomarkers, thirteen had not previously been associated with NSCLC, providing new biological insights into the disease as well as suggesting potential new therapeutic targets.

In addition to the NSCLC protein biomarker discovery, the scientists also demonstrate the utility of the protein-binding reagents used in SOMAscan for direct visualization of protein expression in tissue sections using standard histopathology techniques. SOMAmer (Slow Off-rate Modified Aptamer) binding reagents bind their respective proteins in a manner similar toand as effective asantibodies, but unlike antibodies they can be used in highly multiplexed applications to look at expression differences across thousands of proteins in a single experiment. And as demonstrated in the PLoS ONE paper, SOMAmers can also be used as individual tissue probing agents for pathology studies.


'/>"/>

Contact: Fintan R. Steele, Ph.D.
fsteele@somalogic.com
720-214-3080
SomaLogic, Inc.
Source:Eurekalert

Related medicine news :

1. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
2. Cancer publishes study confirming disparity in breast cancer treatment
3. Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis
4. kajeet Publishes Free Guidelines for Teen and Tween Cell Phone Use
5. Stonebranch Publishes Healthcare IT White Paper
6. ASTRO publishes supplement on protecting cancer patients by reducing radiation doses, side effects
7. EHRtv.com Publishes Over 40 Video Interviews from HIMSS10
8. Dental Practice Marketing Specialist Publishes 1st Article for LIVESTRONG.COM
9. ATS publishes joint statement on renal failure in the ICU patient
10. Questia Online Library Publishes Top Research Topics of 2010 Spring Semester
11. Better Hearing Institute Publishes Comprehensive Consumer Guide to Buying Hearing Aids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... unique liquid food supplements, announced its popular products are now available for purchase ... ALP Nutrition® prioritizes the use of premium natural ingredients in making all of ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider ... announced that Kyle Allain has joined the company as Vice President and General ... including provider, payor and managed care solutions. , A seasoned executive with ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was ... has been at the forefront of Gardant since it was founded in 1999. His ... the opening of more than 40 new senior living communities. With his leadership, Gardant ...
(Date:4/24/2017)... Switzerland (PRWEB) , ... April 24, 2017 , ... ... steps to become familiar. This makes it difficult for lab operators and management ... systematic methodology to help them identify wasteful or unnecessary actions. , Created ...
(Date:4/24/2017)... ... April 24, 2017 , ... “Learning to Use Your SPIRITUAL COMPASS To ... to Use Your SPIRITUAL COMPASS To Navigate Life Issues” is the creation of published ... of the Board of Directors for CONTACT USA, and former member of the American ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Global Surgical ... devices are tubes used to remove excess liquid and ... serum, pus, urine, bile or lymph. Surgical drains are ... surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic ... prophylactic post-surgery to prevent accumulation of fluid e.g. blood ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
Breaking Medicine Technology: